logo
logo
Zoetis Inc.

Zoetis Inc.

NYSE•ZTS
CEO: Ms. Kristin C. Peck
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2013-02-01
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
連絡先情報
10 Sylvan Way, Parsippany, NJ, 07054, United States
973-822-7000
www.zoetis.com
時価総額
$56.47B
PER (TTM)
21.4
56.6
配当利回り
1.6%
52週高値
$177.00
52週安値
$115.25
52週レンジ
21%
順位6
7.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 7.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$2.40B+0.50%
直近4四半期の推移

EPS

$1.63+7.95%
直近4四半期の推移

フリーCF

$805.00M+2.68%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Operational Nine months revenue grew 2% to $7.08B; operational growth reached 3% driven by price increases and franchise strength.
Net Income Rises Sharply Nine months net income attributable to Zoetis increased 9% to $2.07B, reflecting strong operational leverage and lower restructuring costs.
Diluted EPS Up 11% Diluted EPS for nine months reached $4.65, marking an 11% increase compared to $4.18 reported in the prior year period.
Working Capital Significantly Improved Working capital improved to $4.78B as of September 30, 2025, supported by strong operating cash flow generation and debt management.

リスク要因

Foreign Exchange Headwinds Persist FX movements negatively impacted reported revenue growth by approximately 1% for the nine months ended September 30, 2025.
Tax Audit Exposure Noted IRS audit proposes additional tax liability of approximately $450M, creating potential material adverse impact on future tax provisions.
Supply Chain Cost Pressures SG&A expenses increased due to higher compensation and operating costs, partially offsetting gross profit improvements in Q3 2025.
Litigation Contingencies Complex Legal and environmental contingencies involve complex judgments; accrued loss estimates may not reflect final outcomes or potential liabilities.

見通し

New Credit Facility Secured Entered new $1.25B senior unsecured revolving credit facility in August 2025, expiring in December 2027, ensuring liquidity.
Debt Refinancing Completed Issued 2025 Senior Notes to redeem prior notes, managing debt profile; long-term debt increased to $7.07B.
Share Repurchase Authorization Active Board authorized up to $6B repurchase program; $4.5B remains available as of September 30, 2025, for discretionary purchases.
New Accounting Standards Adopted Adopted ASU 2023-09 for income tax disclosures effective January 1, 2025, impacting future annual financial statement disclosures.

同業比較

売上高 (TTM)

Cencora, Inc.COR
$325.78B
+7.4%
The Cigna GroupCI
$274.95B
+11.3%
Elevance Health, Inc.ELV
$199.13B
+12.6%

粗利益率 (最新四半期)

Regeneron Pharmaceuticals, Inc.REGN
88.3%
+3.3pp
argenx SEARGX
88.3%
-53.8pp
Alnylam Pharmaceuticals, Inc.ALNY
84.2%
+1.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
GSK$118.64B15.237.2%29.0%
REGN$78.44B17.214.8%6.7%
CI$76.88B12.814.6%0.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.2%
緩やかな成長
4四半期純利益CAGR
7.5%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月12日
|
EPS:$1.40
|
売上高:$2.36B
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $2.40B+0.5%
    |
    EPS: $1.63+7.9%
    予想通り

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月5日|
    売上高: $2.46B+4.2%
    |
    EPS: $1.61+17.5%
    予想通り

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $2.22B+1.4%
    |
    EPS: $1.41+7.6%
    予想通り

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月13日|
    売上高: $9.26B+8.3%
    |
    EPS: $5.47+7.7%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月4日|
    売上高: $2.39B+11.0%
    |
    EPS: $1.51+17.1%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $2.36B+8.3%
    |
    EPS: $1.37-5.5%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $2.19B+9.5%
    |
    EPS: $1.31+10.1%
    予想通り

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月13日|
    売上高: $8.54B+5.7%
    |
    EPS: $5.08+12.6%
    予想を下回る